文献速递甲状腺疾病

左甲状腺素对老年亚临床甲减患者心血管代谢生物标志物的影响

Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

基于两项双盲随机对照试验的事后分析,纳入286例≥65岁亚临床甲减患者,评估左甲状腺素治疗12个月对血脂及代谢组学指标的影响。总体未见显著效果,但基线TSH≥10 mIU/L者中部分血脂指标有潜在有益变化(多重检验校正后不显著)。

要点

  • 左甲状腺素整体未改善老年亚临床甲减患者的心血管代谢生物标志物。
  • 基线TSH≥10 mIU/L者中部分血脂和脂蛋白有潜在有益变化,但校正后不显著。
  • 结果不支持以心血管代谢标志物为指标对老年亚临床甲减患者常规使用左甲状腺素。

核心结论

  • 在老年亚临床甲减患者中,左甲状腺素治疗对心血管代谢生物标志物无显著影响。
  • 基线TSH≥10 mIU/L者中观察到部分血脂和脂蛋白的潜在有益变化,但多重检验校正后不显著。

研究设计与样本

  • 基于两项双盲随机对照试验基线及12个月数据的事后分析。
  • 纳入286例≥65岁亚临床甲减患者,其中142例随机分配至左甲状腺素组。
  • 中位年龄75(70,82)岁,女性占48%,中位基线TSH 6.44(5.36,7.81)mIU/L。

主要发现

  • 左甲状腺素对ApoB无影响(-0.03 [95% CI: -0.07, 0.00] g/L)。
  • 对Total-C无影响(-0.17 [-0.34, 0.00] mmol/L)。
  • 对non-HDL-C无影响(-0.15 [-0.31, 0.00] mmol/L)。
  • 对RC无影响(-0.09 [-0.16, -0.01] mmol/L)。
  • 对LDL-C无影响(-0.07 [-0.15, 0.02] mmol/L),对TG无影响(-0.07 [-0.15, 0.01] mmol/L)。

关键数值与推荐

  • 在基线TSH≥10 mIU/L者(n=27)中,除HDL-C外所有临床相关血脂指标及含ApoB脂蛋白、VLDL大小和脂肪酸出现潜在有益变化(P < .05,但多重检验校正后不显著)。

临床怎么用

  • 对于老年亚临床甲减患者,不应以改善心血管代谢生物标志物为目的常规处方左甲状腺素。
  • 基线TSH≥10 mIU/L者可能从治疗中获得血脂方面的潜在益处,但需个体化评估。

局限性

  • 为事后分析,可能受到多重检验和样本量限制。
  • 基线TSH≥10 mIU/L亚组样本量小(n=27),结果需谨慎解读。
  • 仅报告12个月数据,长期影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Randomized controlled trials (RCTs) found no cardioprotective effects of levothyroxine therapy in older adults with subclinical hypothyroidism. OBJECTIVE: The aim of this study was to assess levothyroxine effects on cardiometabolic biomarkers, which may serve as more sensitive treatment indicators. DESIGN: Post-hoc analysis using (baseline and 12-month) data from two double-blind RCTs in older adults (≥65 years) with subclinical hypothyroidism. MAIN OUTCOME MEASURE(S): Cardiometabolic biomarkers included seven clinically relevant lipid measures (apolipoprotein B (ApoB), total cholesterol (Total-C), non-high-density lipoprotein cholesterol (non-HDL-C), remnant cholesterol (RC), low-density lipoprotein cholesterol (LDL-C), HDL-C, and triglycerides (TG)) and 167 standardized metabolomic measures from nuclear magnetic resonance. Analyses were additionally stratified by baseline TSH levels. RESULTS: Among 286 included participants (48% women; median age 75 [70, 82] years; median baseline TSH 6.44 [5.36, 7.81] mIU/L), 142 were randomized to levothyroxine. Overall, levothyroxine showed no effects on ApoB (-0.03 [95% CI: -0.07, 0.00] g/L), Total-C (-0.17 [-0.34, 0.00] mmol/L), non-HDL-C (-0.15 [-0.31, 0.00] mmol/L), RC (-0.09 [-0.16, -0.01] mmol/L), LDL-C (-0.07 [-0.15, 0.02] mmol/L), and TG (-0.07 [-0.15, 0.01] mmol/L). In participants with baseline TSH ≥10 mIU/L (n = 27), potentially beneficial changes (P < .05, but not significant after multiple-testing correction) were observed for all clinically relevant lipids except HDL-C, as well as for ApoB-containing lipoproteins, VLDL size, and fatty acids. CONCLUSION: In older adults with subclinical hypothyroidism, levothyroxine treatment showed no effects on cardiometabolic biomarkers, although potentially favorable changes in lipids and lipoproteins were observed for individuals with baseline TSH ≥10 mIU/L.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ao L, Noordam R, Trompet S, et al. Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism. J Clin Endocrinol Metab. 2026. PMID: 41965091. doi:10.1210/clinem/dgag155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。